Skip to main content
SpringerLink
Log in

Recovery of Normal Hematopoiesis after Severe Bone Marrow Aplasia Induced by Interferon-α in a Patient with Chronic Myelogenous Leukemia

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

We describe an interesting case of a patient with chronic myelogenous leukemia (CML) who developed sustained severe bone marrow aplasia after 2 years and 11 months of interferon-α (IFN-α) therapy but demonstrated recovery of normal hematopoiesis when treated with immunosuppressive therapy with granulocyte-colony stimulating factor (G-CSF). Administration of G-CSF resulted in a partial recovery of hematopoiesis, and after starting immunosuppressive therapy, the patient was no longer dependent on blood transfusions. Moreover, her bone marrow had no Philadelphia chromosome-positive clones. According to the results of the present case, bone marrow recovery can be achieved with immunosuppressive therapy and a fatal outcome avoided, even in CML patients suffering from sustained bone marrow aplasia during IFN-a treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.Ann Intern Med. 1991;114:532–528.

    Article  CAS  PubMed  Google Scholar 

  2. Ohnishi K, Ino T, Kishimoto Y, et al. Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis.Cancer Chemother Pharmacol. 2001;48(suppl 1):S59-S64.

    Article  CAS  PubMed  Google Scholar 

  3. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia.Blood. 1987;69:1280–1288.

    PubMed  CAS  Google Scholar 

  4. Gutterman JU, Fine S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.Ann Intern Med. 1982;96:549–556.

    Article  CAS  PubMed  Google Scholar 

  5. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review.J Clin Oncol. 1986;4:234–243.

    Article  CAS  PubMed  Google Scholar 

  6. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.Cancer. 1992;69:410–412.

    Article  CAS  PubMed  Google Scholar 

  7. Shepherd PC, Richards S, Allan NC. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.Br J Haematol. 1994;86:92–96.

    Article  CAS  PubMed  Google Scholar 

  8. Casali M, Truglio F, Milone G, et al. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia.Genes Chrom Cancer. 1992;4:269–270.

    Article  CAS  PubMed  Google Scholar 

  9. Bilhou-Nabera C, Marit G, Devianne I, et al. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia.Genes Chrom Cancer. 1993;6:255–256.

    Article  CAS  PubMed  Google Scholar 

  10. Ariyama T, Inazawa J, Uemura Y, et al. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia.Cancer Genet Cytogenet. 1995;81:20–23.

    Article  CAS  PubMed  Google Scholar 

  11. Motomura S, Sakai R, Tomita N, et al. Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea.Rinsho Ketsueki. 1998;39:302–307.

    PubMed  CAS  Google Scholar 

  12. Fiegl M, Chott A, Seewann HL, Lechner K, Gisslinger H. Persisting bone marrow aplasia following interferon-alpha combined with ara-C for chronic myelogenous leukemia.Leuk Lymphoma. 1999;34:191–195.

    Article  CAS  PubMed  Google Scholar 

  13. Chiusolo P, Sica S, Laurenti L, Piccirillo N, Giordano G, Leone G. Fatal bone marrow aplasia during interferon-α treatment in chronic myelogenous leukemia.Haematologica. 2000;85:212.

    PubMed  CAS  Google Scholar 

  14. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.J Hepatol. 1996;24:38–47.

    Article  CAS  PubMed  Google Scholar 

  15. Mangan KF, Zidar B, Shadduck RK, Zeigler Z, Winkelstein A. Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin.Am J Hematol. 1985;19:401–413.

    Article  CAS  PubMed  Google Scholar 

  16. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia.Haematologica. 1996;81:418–422.

    PubMed  CAS  Google Scholar 

  17. Keung YK, Pettenati MJ, Cruz JM, Powell BL, Woodruff RD, Buss DH. Bone marrow cytogenetic abnormalities of aplastic anemia.Am J Hematol. 2001;66:167–171.

    Article  CAS  PubMed  Google Scholar 

  18. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.Blood. 1997;90:1009–1013.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Hidehiko Saito

    Present address: Nagoya National Hospital, Nagoya, Japan

  2. Mitsune Tanimoto

    Present address: Second Department of Internal Medicine, Okayama University School of Medicine, Okayama

Authors and Affiliations

  1. First Department of Internal Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, 466-8550, Showa-ku, Nagoya, Japan

    Asahi Hishida, Kazuhito Yamamoto, Chiaki Kato, Toshiya Yokozawa, Nobuhiko Emi, Mitsune Tanimoto & Hidehiko Saito

  2. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

    Asahi Hishida

Authors
  1. Asahi Hishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhito Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiaki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiya Yokozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuhiko Emi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitsune Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hidehiko Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhito Yamamoto.

About this article

Cite this article

Hishida, A., Yamamoto, K., Kato, C. et al. Recovery of Normal Hematopoiesis after Severe Bone Marrow Aplasia Induced by Interferon-α in a Patient with Chronic Myelogenous Leukemia. Int J Hematol 77, 55–59 (2003). https://doi.org/10.1007/BF02982603

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02982603

Key words

Search

Navigation